Santen Pharmaceutical Co., Ltd.

TSE:4536.T

1749 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Operating Activities:
Net Income 26,635-14,98327,1896,64521,71431,94335,26123,05453,37324,03226,89325,59127,79131,07428,61015,82320,48221,03920,34118,436
Depreciation & Amortization 18,17817,24917,05516,76816,57310,96910,8969,8829,3386,9583,9263,2902,9492,9763,4214,2094,5934,7614,8244,749
Deferred Income Tax 00000000000000000000
Stock Based Compensation 00000000000000000000
Change In Working Capital 15,701-5,0594,706-21,477-1,976-6,310-2,569-10,234-9,785-6,210-782-6,791-224-4,670-988-1,741-2,021-370894-1,423
Accounts Receivables 18,384-6,443-1,965-7,514-3,054-6,303-7,116-5,489-4,799-7,701-7,672-5,55900000000
Inventory -1,369-1,1445,383-4,590-981-5,000-1,435-4,120-5,388-5211,650-2,588-3,294-1,299-1,438-1,334-1,005-356-18594
Accounts Payables -2,3823,6892,4914,9487172,4455,697-4254,37600000000000
Other Working Capital 1,068-1,161-1,203-14,3211,3422,548-1,134-6,114-4,397-5,689-2,432-4,2033,070-3,371450-407-1,016-14912-2,017
Other Non Cash Items 33,85839,940-2,90736,8723,636-3,708-745-11,859-30,401606-4,079-12,148-9,033-11,611-4,933-6,442-7,586-10,471-5,181-15,143
Operating Cash Flow 72,64937,14746,04338,80839,94732,89442,84310,84322,52525,38625,9589,94221,48317,76926,11011,84915,46814,95920,8786,619
Investing Activities:
Investments In Property Plant And Equipment -10,687-24,588-35,841-23,804-9,228-8,333-9,937-9,500-9,092-66,440-4,786-3,60800000-3,555-2,106-4,906
Acquisitions Net -207-3,470-2,969-29,183-3,4041,475-5,953-19,064-4,097-62,81200000000292,488
Purchases Of Investments -508-589-1,067-3,384-398-931-565-478-2,231-198-4,824-5,183-14,841-5,784-4,626-2,080-3,266-2,208-57-7,728
Sales Maturities Of Investments 4,1272,1493,8703,0703,5032,1562,8791,3832,7034,3332,9314,0495,2274235,4074623,66005245,876
Other Investing Activites 922-279838-544,3522,6985,317-54249,76863,408-4,801-3,461-658-2,315-1,610-4,001-2,477-822801,363
Investing Cash Flow -6,145-26,777-35,169-53,355-5,175-2,935-8,259-28,20137,051-61,709-6,694-4,595-10,272-7,676-829-5,619-2,083-5,845-1,330-2,907
Financing Activities:
Debt Repayment -2,112-11,278-20,460-3,000-500-4,098-8,316-9,524-15,133-37,970000-776-630-5,168-168-168-1,268-5,804
Common Stock Issued 012,227-20,4600-1,38256703,000000005,6415485450000
Common Stock Repurchased -16,962-26,007-120-22-14,124-1-12,38000-6-13,764-2-25-24-15-4,815-16-15-2,582
Dividends Paid -11,881-12,607-11,994-11,188-10,379-10,580-10,559-10,751-9,923-8,264-8,247-8,468-8,705-6,808-6,803-6,798-6,505-5,632-4,759-4,393
Other Financing Activities 21744558,483-2,497-4461281,24599899075,194300675148398156637312514268
Financing Cash Flow -34,031-37,2205,557-16,685-12,729-28,107-17,631-28,657-24,06628,960-7,953-21,557-8,559-1,570-6,753-11,373-11,415-5,691-5,900-12,711
Other Information:
Effect Of Forex Changes On Cash 4,2061,7393,6942,690-1,410-33848-1,501-1,6368891,289972-98-388-135-569-14031375-42
Net Change In Cash 36,679-25,11120,126-28,54220,6341,51317,001-47,51633,875-6,47412,599-15,2382,5538,13418,392-5,7131,8283,73713,724-9,042
Cash At End Of Period 94,58257,90383,01462,88891,43070,79669,28352,28299,79865,92372,39659,79775,03572,48264,34845,95651,66949,84146,10432,380